STORM Therapeutics Secures $56M Financing

STORM Therapeutics, a clinical-stage biotechnology company, announced a successful $56 million Series C financing round. The funding, provided by existing investors including VSR Ventures Private Limited, Pfizer — Pfizer Ventures, Taiho Ventures, IP Group, UTokyo Innovation Platform, and Global Partnership for Education, will support the advancement of STC-15. STC-15, a first-in-class oral small-molecule inhibitor of METTL3, has now entered a Phase 2 monotherapy study for selected sarcoma indications, with the first patient successfully dosed. This trial aims to support potential accelerated regulatory approval and establish a foundation for broader oncology development. STC-15 demonstrated durable tumor regression in Phase 1 studies, targeting METTL3, an RNA-modifying enzyme crucial for cancer stem cell differentiation in sarcomas. Jerry McMahon, CEO of STORM Therapeutics, and Jonathan Trent, MD of the University of Miami, Sylvester Comprehensive Cancer Center, highlighted the significance of this milestone for patients with unmet needs.